SCHEMBL76842

SCHEMBL76842

OC1[C]2CC3CC(C2)CC1C3

nearest known ligand 0.41

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2707599 0.71 CYP2C9 (0.32) CYP2C9
SCHEMBL1714862 0.67
SCHEMBL562775 0.67
SCHEMBL52710 0.67
SCHEMBL3823884 0.67
SCHEMBL384602 0.65 HSD11B1 (0.35)
SCHEMBL7794306 0.64 GAA (0.32)
SCHEMBL5176188 0.63 CYP2C9 (0.32) CYP2C9
SCHEMBL1079244 0.63
SCHEMBL7391545 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113582980-B Compound based on heterocyclic ring and glutarimide skeleton and application thereof 上海科技大学 2023-11-24 CN claimed
CN-113372327-B Glutarimide skeleton-based compound and application thereof 上海科技大学 2023-07-18 CN claimed
US-20230203022-A1 HETEROCYCLE AND GLUTARIMIDE SKELETON-BASED COMPOUND AND APPLICATIONS THEREOF SHANGHAITECH UNIVERSITY (CN) 2023-06-29 US claimed
US-20230132715-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 US claimed
US-20230096517-A1 GLUTARIMIDE SKELETON-BASED COMPOUNDS AND APPLICATION THEREOF SHANGHAITECH UNIVERSITY (CN) 2023-03-30 US claimed
EP-4144728-A1 HETEROCYCLE AND GLUTARIMIDE SKELETON-BASED COMPOUND AND APPLICATIONS THEREOF Shanghaitech University (CN) 2023-03-08 EP claimed
US-20230027752-A1 OPIOID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF FUDAN UNIVERSITY (CN) 2023-01-26 US claimed
EP-4112614-A1 GLUTARIMIDE SKELETON-BASED COMPOUNDS AND APPLICATION THEREOF Shanghaitech University (CN) 2023-01-04 EP claimed
CN-112759545-B 3- (dimethylamino methyl) piperidine-4-alcohol derivative and preparation method and pharmaceutical application thereof 复旦大学 2022-12-13 CN claimed
CN-115160495-A Photoresist film-forming resin containing maleimide structure and preparation method thereof 四川华造宏材科技有限公司 2022-10-11 CN claimed
WO-2005061590-A1 POLYMER PURIFICATION DUPONT ELECTRONIC POLYMERS L.P. (US) 2005-07-07 WO claimed
EP-1509551-A1 PROCESS FOR PURIFICATION OF ALKOXYSTYRENE POLYMERS Dupont Electronic Technologies L.P. (US) 2005-03-02 EP claimed
US-6787611-B2 COPOLYOMERS ARE A MIXTURE OF COMPOUNDS OF VARYING COMPOSITION AND MOLECULAR WEIGHT. TYPICALLY THEY CONTAIN SMALL QUANTITIES OF STARTING MATERIAL AND BY-PRODUCTS WHICH ARE UNDESIRABLE IN THE FINAL POLYMER. THE POLYMER MIXTURE IS PRECIPITATED FROM CHEMFIRST ELECTRONIC MATERIALS L.P. 2004-09-07 US claimed
CN-1498361-A Polymers and photoresist compositions 希普雷公司 2004-05-19 CN claimed
WO-2003089481-A1 PROCESS FPR PURIFICATION OF ALKOXYSTYRENE POLYMERS DUPONT ELECTRONIC TECHNOLOGIES L.P. (US) 2003-10-30 WO claimed
US-20030144470-A1 Purification means CHEMFIRST ELECTRONIC MATERIALS LP 2003-07-31 US claimed
US-6596463-B2 Photosensitivity, resolution, chemical resistance SHIN-ETSU CHEMICAL, CO., LTD. (JP) 2003-07-22 US claimed
US-20020187420-A1 Novel copolymers and photoresist compositions SHIPLEY COMPANY, L.L.C. 2002-12-12 US claimed
WO-2002069044-A2 POLYMERS AND PHOTORESIST COMPOSITIONS SHIPLEY COMPANY, L.L.C. (US) 2002-09-06 WO claimed
US-6312867-B1 Ester compounds, polymers, resist compositions and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2001-11-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230132715-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CYP2C9 3608/4885
US-20230096517-A1 GLUTARIMIDE SKELETON-BASED COMPOUNDS AND APPLICATION THEREOF GLS, GCDH, GLS2 CYP2C9 939/4885
US-20230203022-A1 HETEROCYCLE AND GLUTARIMIDE SKELETON-BASED COMPOUND AND APPLICATIONS THEREOF TNF, GCDH, LITAF CYP2C9 519/4885
US-20230027752-A1 OPIOID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF OPRM1, OPRD1, OPRL1 CYP2C9 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.